Clinical Trial Update: Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel [Phase 1]

View source ↗

Summary

Phase 1 study evaluating a vaccine therapy using recombinant soluble PSMA with the Alhydrogel adjuvant in prostate cancer patients; the trial status is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Alhydrogel (Aluminum hydroxide adjuvant)
• Rs-PSMA (recombinant soluble prostate-specific membrane antigen)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED